Literature DB >> 15326610

Reversible disruption of tight junction complexes in the rat blood-brain barrier, following transitory focal astrocyte loss.

Colin L Willis1, Lopa Leach, Garry J Clarke, Christopher C Nolan, David E Ray.   

Abstract

Breakdown of the blood-brain barrier is a feature of acute and chronic neurodegenerative changes, yet the relationship between astrocytes and the mature barrier remains unclear. We studied this role of astrocytes in vivo using a gliotoxin and evaluated changes in three vascular tight junction markers. Male Fisher F344 rats given systemic 3-chloropropanediol showed astrocytic loss in the inferior colliculus from 12-24 h until the lesion was repopulated 8-28 days later. Within 6 h of astrocyte loss, microvessels in this area began to demonstrate a loss of the normal paracellular localization of the transmembrane proteins occludin and claudin-5 and cytoplasmic zonula occludens-1, which correlated with focal vascular leak of dextran (10 kDa) and fibrinogen. Platelet endothelial adhesion molecule-1 staining revealed that there was no loss of the endothelial lining. Between 4-8 days, severe downregulation of tight junction protein expression was observed, which subsequently returned over the same time period as astrocytes repopulated the lesion. Unexpectedly, dextran and fibrinogen leak from vessels had ceased at 6 days, well before the return of occludin and claudin-5 to appropriate paracellular domains. Control nonvulnerable cortical tissue showed no change in astrocyte morphology and tight junction expression over the same time course. Our data supports a primary role for astrocytic contact in the expression of occludin, claudin-5, and zonula occludens-1 in the mature brain vasculature in vivo. However, barrier integrity to dextran (10 kDa) and fibrinogen can be restored in the absence of astrocytes and tight junction proteins (occludin, claudin-5, and zonula occludens-1).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15326610     DOI: 10.1002/glia.20049

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  44 in total

1.  MRI characterisation of a novel rat model of focal astrocyte loss.

Authors:  M J W Prior; A M Brown; G Mavroudis; T Lister; D E Ray
Journal:  MAGMA       Date:  2004-12-10       Impact factor: 2.310

Review 2.  Blood-brain barrier: structural components and function under physiologic and pathologic conditions.

Authors:  Yuri Persidsky; Servio H Ramirez; James Haorah; Georgette D Kanmogne
Journal:  J Neuroimmune Pharmacol       Date:  2006-07-06       Impact factor: 4.147

Review 3.  Blood-brain barrier integrity and glial support: mechanisms that can be targeted for novel therapeutic approaches in stroke.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 4.  Transporters at CNS barrier sites: obstacles or opportunities for drug delivery?

Authors:  Lucy Sanchez-Covarrubias; Lauren M Slosky; Brandon J Thompson; Thomas P Davis; Patrick T Ronaldson
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 5.  Targeting microvasculature for neuroprotection after SCI.

Authors:  Janelle M Fassbender; Scott R Whittemore; Theo Hagg
Journal:  Neurotherapeutics       Date:  2011-04       Impact factor: 7.620

6.  Neuregulin1-β decreases interleukin-1β-induced RhoA activation, myosin light chain phosphorylation, and endothelial hyperpermeability.

Authors:  Limin Wu; Servio H Ramirez; Allison M Andrews; Wendy Leung; Kanako Itoh; Jiang Wu; Ken Arai; Eng H Lo; Josephine Lok
Journal:  J Neurochem       Date:  2015-11-10       Impact factor: 5.372

7.  Chronic inflammatory pain leads to increased blood-brain barrier permeability and tight junction protein alterations.

Authors:  Tracy A Brooks; Brian T Hawkins; Jason D Huber; Richard D Egleton; Thomas P Davis
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-03-25       Impact factor: 4.733

8.  Selective knockout of astrocytic Na+ /H+ exchanger isoform 1 reduces astrogliosis, BBB damage, infarction, and improves neurological function after ischemic stroke.

Authors:  Gulnaz Begum; Shanshan Song; Shaoxia Wang; Hanshu Zhao; Mohammad Iqbal H Bhuiyan; Eric Li; Rachel Nepomuceno; Qing Ye; Ming Sun; Michael Joseph Calderon; Donna B Stolz; Claudette St Croix; Simon C Watkins; Yinhuai Chen; Pingnian He; Gary E Shull; Dandan Sun
Journal:  Glia       Date:  2017-09-19       Impact factor: 7.452

9.  Tissue-type plasminogen activator and the low-density lipoprotein receptor-related protein induce Akt phosphorylation in the ischemic brain.

Authors:  Jie An; Chen Zhang; Rohini Polavarapu; Xiaohui Zhang; Xiumei Zhang; Manuel Yepes
Journal:  Blood       Date:  2008-07-15       Impact factor: 22.113

Review 10.  Targeted drug delivery to treat pain and cerebral hypoxia.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Pharmacol Rev       Date:  2013-01-23       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.